东大公司于2005年1月1日购入设备一台，设备价款1500万元，预计期末无残值，采用

会计师事务所、律师事务所、投资银行等组织会给员工充分的自由，并按他们的工作成绩给予优厚的报酬，这类组织的文化类型一般是( )。

A．学院式文化

B．俱乐部式文化

C．棒球队式文化

D．堡垒式文化

2010年京沪铁路投入运营，届时北京至上海高速列车全程运行时间只需5小时。京沪铁路全线将优先选用以桥代路的方式开工建设，请问“以桥代路”的主要目的是[ ]

A．展现我国世界一流的铁路修建技术水平

B．防治环境污染

C．节约东部地区的土地资源

D．投资大，拉动我国经济增长

试题五(20分) 某工程，甲施工单位按照施工合同约定，拟将8、F两项分部工程分别分包给乙、丙施工单位。经总监理工程师批准的施工总进度计划如图5—1所示(单位：d)，各项工作匀速进展。

 工程实施过程中发生以下事件。 事 件l：工程开工前，建设单位未将委托给监理单位的监理内容和权限书面告知甲施工单位。甲施工单位向建设单位提交了乙施工单位分包单位资格报审表及营业执 照、企业资质等级证书、安全生产许可文件和分包合同等材料，申请批准乙施工单位进场，建设单位将该报审材料转交给项目监理机构。 事件2：甲施工 单位与乙施工单位签订了B分部工程的分包合同。8分部工程开工45 d后，建设单位要求设计单位修改设计，造成乙施工单位停工l5 d，窝工损失合计8万元。修改设计后，B分部工程价款由原来的500万元增加到560万元。甲施工单位要求乙施工单位在30 d内完成剩余工程，乙施工单位向甲施工单位提出补偿3万元的赶工费，甲施工单位确认了赶工费补偿。 事件3：由于事件2中B分部工程修改设计，乙施工单位向项目监理机构提出工程延期的申请。 事件4：专业监理工程师巡视时发现，已进场准备安装设备的丙施工单位未经项目监理机构进行资格审核。 【问题】

事件1中，分别指出建设单位、甲施工单位做法的不妥之处，说明理由。甲施工单位提交的乙施工单位的分包资格材料还应包括哪些内容

有机磷中毒后瞳孔散大。

The next two questions refer to the following passage:

A pharmaceutical company tested a new painkiller on 1,000 lab rats that were fed large doses of the painkiller for a two-month period. By the end of the experiment, 39 of tile rats had died. The company concluded that the painkiller was sufficiently safe to test on humans.

Which of the following, if true, would cast the most doubt on the pharmaceutical company’s conclusion ？（）

A. Fifteen of the 39 dead rats were later found to have died of a rare form of liver cancer that is generally seen in only 1 out of 600,000 lab rats.

B. The director of the experiment, although a respected scientist, is not a medical doctor, and therefore will not be able to continue as director of the experiment once it switches from animal to human trials.

C. Although the painkiller in question has been shown to block certain forms of pain, its duration of efficacy is less than that of other painkillers currently on the market.

D. Human trials of another drug produced by this pharmaceutical company were called off after 30 out of 1,000 rats died of heart failure during the animal testing phase of the experiment.

E. The pharmaceutical company is eager to introduce new drugs to the market because its best-selling product, a drug that reduces blood pressure, will soon lose its patent protection.